{"links":{"feed":"https://www.erudio.com/reports/a041703-nct03739814/feed.json","html":"https://www.erudio.com/reports/a041703-nct03739814","json":"https://www.erudio.com/reports/a041703-nct03739814.json","markdown":"https://www.erudio.com/reports/a041703-nct03739814.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"a041703-nct03739814"}},"request":"https://www.erudio.com/contact?report=a041703-nct03739814"},"offer":{"cited_clinicians":10,"cited_commentary_sources":23,"verified_hcp_statements":133,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"a041703-nct03739814"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=a041703-nct03739814","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/a041703-nct03739814","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 133 verified statements · 63 from 10 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-09T16:34:41.822449Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":14,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":10,"title":"Primary endpoint: Event-free survival"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Completion of protocol treatment (cohort 3)"},{"claim_count":18,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":20,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":9,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":7,"coverage":"discussed","id":"A1","source_count":4,"title":"MRD, antigen expression and relapse reassessment"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":2,"title":"Maintenance omission and post-treatment surveillance"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":3,"title":"Administration burden, access and patient support"},{"claim_count":19,"coverage":"discussed","id":"A4","source_count":16,"title":"Treatment positioning and perceived significance"},{"claim_count":6,"coverage":"discussed","id":"A5","source_count":2,"title":"Future evidence generation, representation and broader applicability"},{"claim_count":4,"coverage":"discussed","id":"A6","source_count":1,"title":"Separate phase Ib/II inotuzumab–blinatumomab–steroid study in patients over 70"},{"claim_count":10,"coverage":"discussed","id":"A7","source_count":4,"title":"Broader response-adapted escalation, cellular therapy and transplant decisions"}],"counts":{"beyond_population_findings":3,"cited_clinicians":10,"cited_clinicians_by_role":{"physician":2,"physician, Hematology and oncology":3,"physician, Medical oncology":5},"cited_physicians":10,"cited_sources":26,"claims_by_expression_type":{"comparison":21,"experience":7,"interpretation":38,"opinion":33,"primary_context":3,"question":2,"restatement":16,"uncertainty":7,"unspecified":6},"claims_by_kind":{"interpretation":2,"publication_statement":37,"source_observation":94},"clinician_statements":63,"evidence_units":77,"findings":6,"organisational_accounts":4,"people_cited":16,"people_identity_verified":12,"people_total":17,"screened_sources":58,"verified_claims":133},"findings_index":[{"cited_clinicians":3,"id":"F1","structure":{"claims":17,"claims_by_group":{"comparisons":3,"experience":1,"questions":2,"restated":4,"views":7},"limitations":3,"links":{"context":3,"support":18},"ma_question":true,"named_voices":2,"passages":15,"sources":8,"sources_by_kind":{"commentary":6,"media":1,"publication":1}},"title":"Speakers favor a chemotherapy-free option, while one presenter leaves chemotherapy’s added value unresolved"},{"cited_clinicians":4,"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":2,"questions":0,"restated":1,"views":4},"limitations":3,"links":{"context":1,"support":11},"ma_question":true,"named_voices":4,"passages":10,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"publication":1}},"title":"Clinicians cite late toxicity when weighing chemotherapy avoidance, especially after age 70"},{"cited_clinicians":4,"id":"F3","structure":{"claims":13,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":3,"views":5},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":4,"passages":11,"sources":4,"sources_by_kind":{"commentary":1,"media":2,"publication":1}},"title":"One X account favors inotuzumab induction but questions high-risk efficacy and CNS protection"},{"cited_clinicians":3,"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":5},"limitations":3,"links":{"context":2,"support":8},"ma_question":true,"named_voices":2,"passages":8,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"One X account highlights MRD and CD22 as prognostic warning signs"},{"cited_clinicians":0,"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":5},"limitations":4,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"One speaker welcomes POMP omission and favors individualized surveillance"},{"cited_clinicians":3,"id":"F6","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":2,"questions":1,"restated":2,"views":4},"limitations":3,"links":{"context":6,"support":11},"ma_question":true,"named_voices":3,"passages":8,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"In a webinar, unattributed remarks value shorter treatment but question continuous-infusion access"}],"open_question":{"basis":"From finding F1 (17 statements from 2 speakers in 8 sources)","cited_claim_ids":["claim-d0e5e85c878e2b086d09","claim-00f7020dc35953ac8bdc","claim-04262089ac369b31083a","claim-7a5391ec6c2b3e15c684","claim-8aa6e543db710fdd0ab6","claim-d6ec2d7c2d468e56118f","claim-f8298c7ade4ff8825ee7","claim-31e86c6334acd5f698d2","claim-5090e2fc64f390bab7c7","claim-4082ce08fd3b2d350b86","claim-4f924a5df04df92fa82a","claim-e010105dccd5350c5e6a","claim-6f9a4019d04834ebddc6","claim-ed0188127a9e8a9a67dc","claim-f6b321f78f0ee30257b6"],"finding_ids":["F1"],"question":"What do clinicians need to see on event-free survival, overall survival and non-relapse mortality from a randomized comparison of A041703’s inotuzumab–blinatumomab sequence with versus without systemic chemotherapy in adults aged 60 or older with newly diagnosed Ph-negative, CD22-positive B-ALL?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Treatment positioning: enthusiasm without a proven chemotherapy-addition answer"},{"id":"section-2","level":2,"title":"Safety: late mortality motivates chemotherapy avoidance, but relative safety is not zero risk"},{"id":"section-3","level":2,"title":"Induction choice and CNS protection: complementary drug roles, qualified confidence"},{"id":"section-4","level":2,"title":"MRD, CD22 and antigen escape: remission is not the end of risk assessment"},{"id":"section-5","level":2,"title":"Maintenance and surveillance: less treatment, but continued vigilance"},{"id":"section-6","level":2,"title":"Treatment burden and access: outpatient delivery still needs substantial support"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"A separate over-70 steroid-containing study: supportive rationale, immature outcomes"},{"id":"section-9","level":3,"title":"Broader MRD-directed escalation and transplant choices"},{"id":"section-10","level":2,"title":"Scope and coverage"},{"id":"section-11","level":3,"title":"Hoped-for relevance in younger patients"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":2}],"id":"T1","label":"Primary endpoint: Event-free survival"},{"findings":[],"id":"T2","label":"Primary endpoint: Completion of protocol treatment (cohort 3)"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-09T16:34:41.822449Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-09T16:48:22Z","record_hash":"0a3487de36042e7af06f23adc760c09b880d2a06cfe57a0b48728496ef06e823","release_hash":"f057d52c65b5c898ac2e3bf3c94f918e173c0c25748d9f14df63436798853cc3","report_id":"erudio-nct03739814","run_id":"d20bc9f4-ef46-4263-9ee2-9788d4a23f6d","schema_version":"5.0","slug":"a041703-nct03739814","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"One physician regards A041703 as a potential treatment standard because of reduced chemotherapy-related toxicity, while noting shorter follow-up. A hematologist-oncologist described in the sources as the trial’s presenter, a principal investigator and a results author considers remissions apparently durable with longer follow-up, but seeks randomized evidence before ruling out added benefit from chemotherapy. Hoped-for relevance to younger patients remains unproven.","examples":[],"meta_description":"58 sources screened · 133 verified statements (63 from clinicians verified by NPI or staff page) from 26 sources · 6 findings. Updated Nov 9, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-09T16:48:22Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":58},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on post-treatment MRD surveillance intervals for older adults who completed therapy with MRD negativity during treatment.","34 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 30 sources about other trials or topics are not included.","This is an account of the sources reviewed for this edition, not all HCPs or all public discussion. Comments that do not name the trial or use different terminology or transcription may be missing.","The clinical discussion overwhelmingly concerns Cohort 1 in older patients with newly diagnosed Ph-negative, CD22-positive B-ALL. It cannot support equivalent conclusions for relapsed/refractory disease or the other cohorts.","The published study is small and nonrandomized. Historical and cross-study comparisons involve different populations, time periods, regimens and follow-up, so they cannot establish chemotherapy’s incremental benefit or comparative safety.","The publication reports median follow-up of 30 months; the extended presentation reports 45 months. These analyses and earlier summaries should not be treated as one contemporaneous dataset.","MRD associations are limited by sample availability, detectable ASO-PCR clones and assay sensitivity. They do not establish a treatment-selection effect or a validated escalation algorithm.","Some reported numbers and disease labels differ between sources. The report preserves those differences as attributed statements rather than silently correcting them.","Some remarks cannot be assigned to a named participant, and clinical roles are not established for every named account or speaker. Trial-involvement descriptions come from the sources themselves, not independent confirmation.","No separate protocol was available. Lack of commentary on an indexed topic means no substantive discussion was found in the material reviewed, not that clinicians have no concerns about it."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":0,"publication":3,"registry":0,"regulatory":0,"x_thread":15,"x_video":1,"youtube":4},"by_evidence_role":{"commentary":23,"context":3},"count":26,"evidence_window":{"end":"2026-11-06","start":"2023-10-22"},"retrieval_snapshot":"2026-11-09T15:31:26.896848Z","timeline":[{"count":1,"week":"2023-W42"},{"count":2,"week":"2024-W08"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W40"},{"count":3,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W48"},{"count":3,"week":"2025-W49"},{"count":2,"week":"2026-W03"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W43"},{"count":2,"week":"2026-W45"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT03739814:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03739814:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:35622074","quote_policy":"short_quote_link_out"},{"id":"pubmed:41026957","quote_policy":"short_quote_link_out"},{"id":"pubmed:41671463","quote_policy":"short_quote_link_out"},{"id":"openfda:38b482a8-960b-4591-9857-5031ecb830aa:20260414","quote_policy":"short_quote_link_out"},{"id":"openfda:cc7014b1-c775-411d-b374-8113248b4077:20260206","quote_policy":"short_quote_link_out"},{"id":"openfda:16d804b6-4957-43ee-b18c-3b36ec37c5ac:20260814","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-3mf5wnwn6o7ugsjcqwk4c5rj-3m3r4qppdls2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-44sbtatqqeqwv6jlnhkx7zkj-3m3pvypqzjl27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-44sbtatqqeqwv6jlnhkx7zkj-3m65mbefbop2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-44sbtatqqeqwv6jlnhkx7zkj-3m73i3r23uw24","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-44sbtatqqeqwv6jlnhkx7zkj-3m7fqx2bwtc2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-44sbtatqqeqwv6jlnhkx7zkj-3mznvmokpx22a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogu7udgs2khcvgdkx6cqbalk-3m7furgakak2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tekhmoswn2dxysqe7c73fzlt-3mxjthvwzfc2n","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1069604728227725312:1e35f2e7-1521-4918-8637-a5844a5f587c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1083388045540380673:734d5234-a2d2-4452-a6c7-e895ea7114ca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1092860743362465792:fb321d1d-893b-4afa-8c73-af2f1ce03c59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1107997825823055875:62d32c03-70fe-4064-bdf0-6aef3f227a7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1151123110718033920:8224a469-bfec-4f20-8732-b1d68d3b5780","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1163807963334828032:a5101d84-83ef-49c9-97ff-bbd9abafda3e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1168882672275513346:cb0dead4-e505-4788-9042-445441aa36f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1201905224505602048:c066d157-d011-41ec-9295-170fd4c6a74f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1278727680301694976:c1608a90-fa95-45bb-86d4-d4fd29a09f42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1336348577027792898:0f8c1641-fe28-4bb0-aa9a-5aaadd565f29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1343929788868640770:af197236-ac72-453d-a5fd-b9620edb9a54","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1440344216605917190:c2d2272c-bf88-4ad6-9de1-7d993d8206e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1491851438653382662:f2b764a2-ee48-4205-8c41-66a4a1281b70","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1606374432628477959:39e5857f-bae0-44b0-b1ed-c8d41a0650b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1658311422474956800:310f7df6-4edd-4e7b-872b-19f4d871805f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1662869909414588416:98cf8d2e-24af-43e9-900e-bcd065e4489b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1664724835463831552:819fca68-bc97-4873-a4ec-f64041e2ee4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716205178188182008:8c64b59e-5681-48b2-8871-4382efdd302f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1725272529713946710:82da3687-5bd6-4447-82cc-4efe25f3475e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761070328233467963:bd724464-c5d0-492d-8956-110a99c38dd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1761070958268363134:8c976de0-2dad-4175-a885-b8b2cd160178","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1881033398778495341:756aa296-410b-4be0-b0a9-30008e731ba4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1883170111449645544:72edd9da-e502-4b7c-afe5-7f116e785154","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963236267534983554:361c25ab-fcd6-4378-a3f1-a8c3b48da97e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973231484707414337:df843ecb-0e1c-4e1f-9853-0e4ca9d8a991","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973556721458225258:3258bb81-c051-4ce3-a0dd-bfe6afc33dcc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1976271909458182434:038b2faa-52e6-4592-83f1-f8203aceb170","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980682949210304583:7f38c1a7-f8d2-410c-b953-e151c6b2ee4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980849724438540450:ef52bc04-291e-408e-86fd-4e62c0cfdd6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981709518028358017:9dcc69be-09ab-4e46-834c-d13dd24be351","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1986123483672097129:7feec2db-75b1-452f-a5a6-a328f1e63b43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991816459467542758:60807b02-9484-4bb6-b203-f0a0db729057","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991891917165002762:edd096b4-10b6-47ef-9802-3474022bdb07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1994136135140774399:06cb625d-a6e1-482e-beff-26f2ff16d9ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997678797311610942:2fe9ffd9-25e6-4551-a02e-716218dc31f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997703803156763106:2a439a4e-d415-4d61-b9bf-e9546fa75789","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997714562779345274:fb2c5a4d-e461-4b98-a6be-c214c7fc61a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998338505630470238:e9212308-74c4-4618-9805-cddbcf1840e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2006731356395720708:01b6b3aa-759d-4692-8007-9ceea0128cd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2011393892562649350:b916f47d-91c5-4e07-81a9-7e4bf5214638","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032377837089411171:c47d7c52-f6e5-48f7-8825-ed530d518fc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2032378432470880673:cc8bffda-ebc0-4c13-84c4-7319844c8145","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050574622882418965:568f5414-e19c-4c2e-a3a9-900cd47454a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108943196143464939:c9fad83c-432a-4b34-8471-a642e9298195","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118756615692128289:039656a1-b55f-4c73-9e42-5fec1af3a89e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2011393892562649350","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:-yFre0eQ2D4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:QneuXjqWgUk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YF0WmCG6Nlo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ciPPV1iY8u8","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":45,"x_video":1,"youtube":4},"by_evidence_role":{"commentary":58},"count":58,"evidence_window":{"end":"2026-11-06","start":"2018-12-03"},"retrieval_snapshot":"2026-11-09T15:31:26.896848Z","timeline":[{"count":1,"week":"2018-W49"},{"count":1,"week":"2019-W02"},{"count":1,"week":"2019-W06"},{"count":1,"week":"2019-W12"},{"count":1,"week":"2019-W29"},{"count":1,"week":"2019-W34"},{"count":1,"week":"2019-W36"},{"count":1,"week":"2019-W49"},{"count":1,"week":"2020-W27"},{"count":1,"week":"2020-W50"},{"count":1,"week":"2020-W53"},{"count":1,"week":"2021-W38"},{"count":1,"week":"2022-W06"},{"count":1,"week":"2022-W51"},{"count":1,"week":"2023-W20"},{"count":1,"week":"2023-W21"},{"count":1,"week":"2023-W22"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2023-W46"},{"count":2,"week":"2024-W08"},{"count":1,"week":"2024-W38"},{"count":1,"week":"2025-W02"},{"count":1,"week":"2025-W03"},{"count":1,"week":"2025-W04"},{"count":1,"week":"2025-W36"},{"count":2,"week":"2025-W40"},{"count":1,"week":"2025-W41"},{"count":5,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":3,"week":"2025-W47"},{"count":1,"week":"2025-W48"},{"count":6,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W01"},{"count":2,"week":"2026-W03"},{"count":2,"week":"2026-W11"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W41"},{"count":1,"week":"2026-W43"},{"count":2,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":5,"linkedin_post":0,"other":0,"podcast":0,"publication":37,"registry":0,"regulatory":0,"x_thread":41,"x_video":3,"youtube":47}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: blinatumomab","status":"unmapped"},{"reason":"Unmapped registry intervention: inotuzumab ozogamicin","status":"unmapped"},{"reason":"Unmapped registry intervention: ponatinib","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","status":"unmapped"},{"reason":"Unmapped registry condition: Recurrent B Acute Lymphoblastic Leukemia","status":"unmapped"},{"reason":"Unmapped registry condition: Refractory B Acute Lymphoblastic Leukemia","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"A041703","aliases":["A041703","Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease"],"brief_title":"Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","Recurrent B Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia"],"display_condition":"CD22-positive B-lineage acute lymphoblastic leukemia","display_interventions":[["inotuzumab ozogamicin","blinatumomab"],["inotuzumab ozogamicin","blinatumomab","ponatinib"]],"enrollment":{"count":84,"type":"ESTIMATED"},"interventions":[{"name":"Biospecimen Collection","synonyms":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Blinatumomab","synonyms":["AMG 103","AMG-103","AMG103","Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","Blincyto","MEDI 538","MEDI-538","MEDI538","MT 103","MT-103","MT103"],"type":"BIOLOGICAL"},{"name":"Bone Marrow Aspiration","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"PROCEDURE"},{"name":"Bone Marrow Biopsy","synonyms":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"],"type":"PROCEDURE"},{"name":"Inotuzumab Ozogamicin","synonyms":["Besponsa","CMC 544","CMC-544","CMC544","Way 207294","WAY-207294"],"type":"BIOLOGICAL"},{"name":"Lumbar Puncture","synonyms":["LP","Spinal Tap"],"type":"PROCEDURE"},{"name":"Ponatinib","synonyms":["AP 24534","AP-24534","AP24534"],"type":"DRUG"}],"nct_id":"NCT03739814","official_title":"A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease","overall_status":"RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2027-02-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Will be defined as time from start of treatment to failure to achieve complete response (CR)/complete response with incomplete count recovery (CRi) after completing Course II of blinatumomab, relapse after CR/CRi, progression on study requiring withdrawal from study therapy, or death from any cause","measure":"Event-free survival","timeFrame":"At 1 year"},{"description":"Feasibility defined as completion of the planned therapy as defined in the protocol. Success rate defined as the proportion of patients who either complete entire protocol treatment or go off protocol treatment due to the disease (e.g., refractory disease, progression, and relapse).","measure":"Completion of protocol treatment (cohort 3)","timeFrame":"Up to 10 years"}],"registered_date":{"date":"2018-11-14","type":"ACTUAL"},"registry_last_updated":"2026-10-28","registry_url":"https://clinicaltrials.gov/study/NCT03739814","short_name":"A041703","short_name_basis":"canonical_name","sponsor":"National Cancer Institute (NCI)","start_date":{"date":"2019-05-08","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase2","study_ids":[{"id":"NCI-2018-02484","type":"sponsor_study_id"},{"domain":"Alliance for Clinical Trials in Oncology; CTEP","id":"A041703","type":"other"},{"id":"U10CA180821","type":"nih"}],"study_type":"INTERVENTIONAL"}}}